BD 2025 Strategic Investments Driving Growth and Advancing Innovation; Company Raises Mid-point of Revenue and Adjusted EPS Guidance Ranges Revenue of $4.8 billion increased 1.5% as reported and 4.1% on a currency-neutral basis Revenue from base business (which excludes COVID-only diagnostic testing) […]

FRANKLIN LAKES, N.J., Feb. 15, 2023 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced that the company has been named to America’s Best Large Employers List 2023 by Forbes, furthering its progress against the company’s environmental, […]

Execution of BD 2025 Strategy Delivering Consistent and Durable Performance Revenue of $4.6 billion decreased 2.8% as reported and increased 1.7% on a currency-neutral basis Revenue from base business (which excludes COVID-only diagnostic testing) grew 0.4% as reported, 5.2% currency-neutral GAAP and […]

Execution of BD 2025 Strategy Driving Consistent Durable Growth Q4 revenue from continuing operations of $4.8 billion decreased 1.8% as reported and increased 2.3% on a currency-neutral basis Q4 revenue performance driven by base revenue growth of 4.2% as reported, 8.6% currency-neutral […]

Mike Garrison Named EVP and President, Medical segment Rick Byrd Named EVP and President, Interventional segment FRANKLIN LAKES, N.J., Aug. 25, 2022 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the appointment of two senior leaders […]

FRANKLIN LAKES, N.J., Aug. 8, 2022 /PRNewswire/ — Becton, Dickinson and Company (NYSE: BDX) (the “Company” or “BD“) today announced that it has commenced tender offers to purchase for cash the debt securities issued by the Company listed in the table below (collectively, […]

Revenue from continuing operations of $4.6 billion increased 0.7% as reported and 3.8% on currency-neutral basis Revenue from continuing operations driven by base revenue growth of 6.0% as reported, 9.3% currency-neutral Worldwide COVID-only testing revenues of $76 million declined from $300 million in the prior year […]

Revenue of $5.0 billion increased 2.1% as reported and 3.9% on currency-neutral basis Revenue driven by base revenue growth of 8.2% as reported, 10.2% currency-neutral, partially offset by decline in worldwide COVID-only testing revenues to $214 million from $474 million in the prior year GAAP diluted […]